Epidyolex takes huge step toward EU licensing

A European review committee has recommended that British company GW Pharmaceuticals’ Epidyolex (known as Epidiolex in the US) be licensed as a medicine in the European Union. It could become the first official CBD-based medicine available in Europe after the panel recommended the licensing of therapeutic drugs in the union.

Read full article

Download the full news analysis

"*" indicates required fields

Corporate Email*

Company Name*

Name*

Department*

Industry*

Work Telephone*

How did you hear about us?*

Name

This field is for validation purposes and should be left unchanged.

I'm already a subscriber

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

LATEST ALERTS

Epidyolex takes huge step toward EU licensing

CannIntelligence

Our Key Benefits

Sign up to our newsletter

LATEST ALERTS

Download the full news analysis

CannIntelligence

Our Key Benefits

Thanks for getting in touch with us

Sign up to our newsletter

Start your FREE trial